Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types

Journal of Circulating Biomarkers

Volumn 5, Issue , 2016, Pages

  Lepone, Lauren M ^a   Donahue, Renee N ^a   Grenga, Italia ^a   Metenou, Simon ^a   Richards, Jacob ^a   Heery, Christopher R ^a   Madan, Ravi A ^a   Gulley, James L ^a   Schlom, Jeffrey ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Age; Cancer; Multicolour Flow Cytometry; Peripheral Blood Mononuclear Cells

Indexed keywords

EID: 84978156184     PISSN: None     EISSN: 18494544     Source Type: Journal    
DOI: 10.5772/62322     Document Type: Article

References (65)

1. Whiteside TL. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol. 2006;16:3–15. DOI:10.1016/j.semcancer.2005.07.008
2. Desai A, Grolleau-Julius A, Yung R. Leukocyte function in the aging immune system. J Leukoc Biol. 2010;87:1001–9. DOI:10.1189/jlb.0809542
3. Zanussi S, Serraino D, Dolcetti R, Berretta M, De Paoli P. Cancer, aging and immune reconstitution. Anticancer Agents Med Chem. 2013;13:1310–24
4. Chattopadhyay PK, Roederer M. Cytometry: Today's technology and tomorrow's horizons. Methods. 2012;57:251–8. DOI:10.1016/j.ymeth. 2012.02.009
5. Perfetto SP, Chattopadhyay PK, Roederer M. Seventeen-colour flow cytometry: Unravelling the immune system. Nat Rev Immunol. 2004;4:648–55. DOI:10.1038/nri1416
6. Camous X, Pera A, Solana R, Larbi A. NK cells in healthy aging and age-associated diseases. J Biomed Biotechnol. 2012; 2012: 195956. DOI:10.1155/2012/195956
7. Howlader N Na, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, (eds). SEER Cancer Statistics Review 1975–2012. National Cancer Institute; 2015; Available from: http://seer.cancer.gov/csr/1975_2012/ [Accessed: 2015-10-5]
8. Jochems C, Tucker JA, Tsang KY, Madan RA, Dahut WL, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: Immune correlates. Cancer Immunol Immunother. 2014; 63: 407–18. DOI: 10.1007/s00262-014-1524-0
9. Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL. Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol. 2012; 39: 296–304. Epub 2012/05/19. DOI:10.1053/j.seminoncol. 2012. 02.010
10. Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, Schlom J. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015. DOI:10.1158/2326-6066.CIR-15-0059
11. Idorn M, Kollgaard T, Kongsted P, Sengelov L, Straten P Thor. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother. 2014;63:1177–87. DOI:10.1007/s00262-014-1591-2
12. Feise RJ. Do multiple outcome measures require p-value adjustment? BMC Med Res Methodol. 2002;2:8
13. Baitsch L, Legat A, Barba L, Marraco SA Fuertes, Rivals JP, Baumgaertner P, Christiansen-Jucht C, Bouzourene H, Rimoldi D, Pircher H, Rufer N, Matter M, Michielin O, Speiser DE. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One. 2012;7:e30852. DOI:10.1371/journal.pone.0030852
14. Foks AC, Ran IA, Wasserman L, Frodermann V, Ter Borg MN, de Jager SC, van Santbrink PJ, Yagita H, Akiba H, Bot I, Kuiper J, van Puijvelde GH. T-cell immunoglobulin and mucin domain 3 acts as a negative regulator of atherosclerosis. Arterioscler Thromb Vasc Biol. 2013;33:2558–65. DOI:10.1161/ATVBAHA.113.301879
15. Quigley M, Pereyra F, Nilsson B, Porichis F, Fonseca C, Eichbaum Q, Julg B, Jesneck JL, Brosnahan K, Imam S, Russell K, Toth I, Piechocka-Trocha A, Dolfi D, Angelosanto J, Crawford A, Shin H, Kwon DS, Zupkosky J, Francisco L, Freeman GJ, Wherry EJ, Kaufmann DE, Walker BD, Ebert B, Haining WN. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med. 2010;16:1147–51. DOI:10.1038/nm.2232
16. D'Cruz LM, Rubinstein MP, Goldrath AW. Surviving the crash: Transitioning from effector to memory CD8+ T cell. Semin Immunol. 2009;21:92–8. DOI: 10.1016/j.smim.2009.02.002
17. Sansom DM, Walker LS. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol Rev. 2006; 212:131–48. DOI: 10.1111/j.0105-2896. 2006.00419.x
18. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V, Chouaib S. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211:781–90. DOI:10.1084/jem.20131916
19. Duffy A, Zhao F, Haile L, Gamrekelashvili J, Fioravanti S, Ma C, Kapanadze T, Compton K, Figg WD, Greten TF. Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies. Cancer Immunol Immunother. 2013;62:299–307. DOI:10.1007/s00262-012-1332-3
20. Ma Y, Shurin GV, Gutkin DW, Shurin MR. Tumor associated regulatory dendritic cells. Semin Cancer Biol. 2012;22:298–306. DOI:10.1016/j.semcancer. 2012.02.010
21. Thibult ML, Mamessier E, Gertner-Dardenne J, Pastor S, Just-Landi S, Xerri L, Chetaille B, Olive D. PD-1 is a novel regulator of human B-cell activation. Int Immunol. 2013;25:129–37. DOI:10.1093/intimm/dxs098
22. Barclay AN, Wright GJ, Brooke G, Brown MH. CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol. 2002;23:285–90. Epub 2002/06/20
23. Martinez-Barriocanal A, Sayos J. Molecular and functional characterization of CD300b, a new activating immunoglobulin receptor able to transduce signals through two different pathways. J Immunol. 2006;177:2819–30. Epub 2006/08/22
24. Tedder TF, Poe JC, Fujimoto M, Haas KM, Sato S. The CD19-CD21 signal transduction complex of B lymphocytes regulates the balance between health and autoimmune disease: Systemic sclerosis as a model system. Curr Dir Autoimmun. 2005;8:55–90. Epub 2004/11/27. DOI:10.1159/000082087
25. Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol. 1997;15:481–504. Epub 1997/01/01. DOI:10.1146/annurev.immunol.15.1.481
26. Yamazaki T, Nagumo H, Hayashi T, Sugane K, Agematsu K. CD72-mediated suppression of human naive B cell differentiation by down-regulating X-box binding protein 1. Eur J Immunol. 2005;35:2325–34. Epub 2005/07/28. DOI:10.1002/eji.200425639
27. Schmitt C, Tonnelle C, Dalloul A, Chabannon C, Debre P, Rebollo A. Aiolos and Ikaros: Regulators of lymphocyte development, homeostasis and lymphoproliferation. Apoptosis. 2002;7:277–84. Epub 2002/05/09
28. Lu X, Sicard R, Jiang X, Stockus JN, McNamara G, Abdulreda M, Moy VT, Landgraf R, Lossos IS. HGAL localization to cell membrane regulates B-cell receptor signaling. Blood. 2015;125:649–57. Epub 2014/11/09. DOI: 10.1182/ blood-2014-04-571331
29. Roederer M, Tarnok A. OMIPs – Orchestrating multiplexity in polychromatic science. Cytometry A. 2010;77:811–2. Epub 2010/08/20. DOI:10.1002/cyto.a.20959
30. Brinkman RR, Aghaeepour N, Finak G, Gottardo R, Mosmann T, Scheuermann RH. State-of-the-Art in the Computational Analysis of Cytometry Data. Cytometry A. 2015;87:591–3. Epub 2015/06/26. DOI: 10.1002/cyto.a.22707
31. Robinson JP, Rajwa B, Patsekin V, Davisson VJ. Computational analysis of high-throughput flow cytometry data. Expert Opin Drug Discov. 2012;7:679–93. Epub 2012/06/20. DOI:10.1517/17460441.2012.693475
32. Castelo-Branco C, Soveral I. The immune system and aging: A review. Gynecol Endocrinol. 2014;30:16–22. DOI:10.3109/09513590.2013.852531
33. Ligthart GJ, Corberand JX, Fournier C, Galanaud P, Hijmans W, Kennes B, Muller-Hermelink HK, Steinmann GG. Admission criteria for immunogerontological studies in man: The SENIEUR protocol. Mech Ageing Dev. 1984;28:47–55
34. Plackett TP, Boehmer ED, Faunce DE, Kovacs EJ. Aging and innate immune cells. J Leukoc Biol. 2004;76:291–9. DOI:10.1189/jlb.1103592
35. Czesnikiewicz-Guzik M, Lee WW, Cui D, Hiruma Y, Lamar DL, Yang ZZ, Ouslander JG, Weyand CM, Goronzy JJ. T cell subset-specific susceptibility to aging. Clin Immunol. 2008;127:107–18. DOI:10.1016/j.clim.2007.12.002
36. Gregg R, Smith CM, Clark FJ, Dunnion D, Khan N, Chakraverty R, Nayak L, Moss PA. The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age. Clin Exp Immunol. 2005; 140: 540–6. DOI: 10.1111/j. 1365-2249. 2005.02798.x
37. Verschoor CP, Johnstone J, Millar J, Dorrington MG, Habibagahi M, Lelic A, Loeb M, Bramson JL, Bowdish DM. Blood CD33(+)HLA-DR(−) myeloid-derived suppressor cells are increased with age and a history of cancer. J Leukoc Biol. 2013; 93:633–7. DOI: 10.1189/jlb. 0912461
38. Borrego F, Alonso MC, Galiani MD, Carracedo J, Ramirez R, Ostos B, Pena J, Solana R. NK phenotypic markers and IL2 response in NK cells from elderly people. Exp Gerontol. 1999;34:253–65
39. Gayoso I, Sanchez-Correa B, Campos C, Alonso C, Pera A, Casado JG, Morgado S, Tarazona R, Solana R. Immunosenescence of human natural killer cells. J Innate Immun. 2011;3:337–43. DOI: 10.1159/000328005
40. Le Garff-Tavernier M, Beziat V, Decocq J, Siguret V, Gandjbakhch F, Pautas E, Debre P, Merle-Beral H, Vieillard V. Human NK cells display major phenotypic and functional changes over the life span. Aging Cell. 2010;9:527–35. DOI: 10.1111/j. 1474-9726. 2010. 00584.x
41. Pawelec G, Hirokawa K, Fulop T. Altered T cell signalling in ageing. Mech Ageing Dev. 2001;122:1613–37
42. Santegoets SJ, Stam AG, Lougheed SM, Gall H, Scholten PE, Reijm M, Jooss K, Sacks N, Hege K, Lowy I, Cuillerot JM, von Blomberg BM, Scheper RJ, van den Eertwegh AJ, Gerritsen WR, de Gruijl TD. T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother. 2013;62:245–56. DOI: 10.1007/s00262-012-1330-5
43. Caras I, Grigorescu A, Stavaru C, Radu DL, Mogos I, Szegli G, Salageanu A. Evidence for immune defects in breast and lung cancer patients. Cancer Immunol Immunother. 2004;53:1146–52. DOI: 10.1007/s00262-004-0556-2
44. Evans CF, Galustian C, Bodman-Smith M, Dalgleish AG, Kumar D. The effect of colorectal cancer upon host peripheral immune cell function. Colorectal Dis. 2010; 12: 561–9. DOI: 10.1111/j. 1463-1318.2009.01819.x
45. Heuvers ME, Muskens F, Bezemer K, Lambers M, Dingemans AM, Groen HJ, Smit EF, Hoogsteden HC, Hegmans JP, Aerts JG. Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients. Lung Cancer. 2013;81:468–74. DOI:10.1016/j.lungcan.2013.06.005
46. Melichar B, Touskova M, Solichova D, Kralickova P, Kopecky O. CD4(+) T-lymphocytopenia and systemic immune activation in patients with primary and secondary liver tumours. Scandinavian Journal of Clinical & Laboratory Investigation. 2001;61:363–70. DOI: 10.1080/003655101316911404
47. Wang L, Chang EW, Wong SC, Ong SM, Chong DQ, Ling KL. Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J Immunol. 2013;190:794–804. DOI:10.4049/jimmunol.1202088
48. Yamamoto T, Yanagimoto H, Satoi S, Toyokawa H, Yamao J, Kim S, Terakawa N, Takahashi K, Kwon AH. Circulating myeloid dendritic cells as prognostic factors in patients with pancreatic cancer who have undergone surgical resection. J Surg Res. 2012;173:299–308. DOI:10.1016/j.jss.2010.09.027
49. MacFarlane AW, Jillab M, Plimack ER, Hudes GR, Uzzo RG, Litwin S, Dulaimi E, Al-Saleem T, Campbell KS. PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection. Cancer Immunol Res. 2014;2:320–31. DOI:10.1158/2326-6066.CIR-13-0133
50. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704. DOI:10.1146/annurev.immunol.26.021607.090331
51. Elkord E, Alcantar-Orozco EM, Dovedi SJ, Tran DQ, Hawkins RE, Gilham DE. T regulatory cells in cancer: Recent advances and therapeutic potential. Expert Opin Biol Ther. 2010;10:1573–86. DOI:10.1517/14712598.2010.529126
52. Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci. 2014;1319:47–65. DOI:10.1111/nyas.12469
53. Yokokawa J, Cereda V, Remondo C, Gulley JL, Arlen PM, Schlom J, Tsang KY. Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res. 2008;14:1032–40. DOI: 10.1158/ 1078-0432. CCR-07-2056
54. Strauss L, Bergmann C, Gooding W, Johnson JT, Whiteside TL. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:6301–11. DOI: 10.1158/1078-0432.CCR-07-1403
55. Baine MJ, Chakraborty S, Smith LM, Mallya K, Sasson AR, Brand RE, Batra SK. Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility. PLoS One. 2011;6:e17014. Epub 2011/02/25. DOI:10.1371/journal.pone.0017014
56. Kiaii S, Clear AJ, Ramsay AG, Davies D, Sangaralingam A, Lee A, Calaminici M, Neuberg DS, Gribben JG. Follicular lymphoma cells induce changes in T-cell gene expression and function: Potential impact on survival and risk of transformation. J Clin Oncol. 2013;31:2654–61. Epub 2013/06/19. DOI:10.1200/JCO.2012.44.2137
57. Herazo-Maya JD, Noth I, Duncan SR, Kim S, Ma SF, Tseng GC, Feingold E, Juan-Guardela BM, Richards TJ, Lussier Y, Huang Y, Vij R, Lindell KO, Xue J, Gibson KF, Shapiro SD, Garcia JG, Kaminski N. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med. 2013;5:205ra136. Epub 2013/10/04. DOI:10.1126/scitranslmed.3005964
58. Sitras V, Fenton C, Acharya G. Gene expression profile in cardiovascular disease and preeclampsia: A meta-analysis of the transcriptome based on raw data from human studies deposited in Gene Expression Omnibus. Placenta. 2015;36:170–8. Epub 2015/01/04. DOI:10.1016/j.placenta.2014.11.017
59. Ma J, Lin Y, Zhan M, Mann DL, Stass SA, Jiang F. Differential miRNA expressions in peripheral blood mononuclear cells for diagnosis of lung cancer. Lab Invest. 2015;95:1197–206. Epub 2015/07/07. DOI:10.1038/labinvest.2015.88
60. Komatsu N, Matsueda S, Tashiro K, Ioji T, Shichijo S, Noguchi M, Yamada A, Doi A, Suekane S, Moriya F, Matsuoka K, Kuhara S, Itoh K, Sasada T. Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination. Cancer. 2012;118:3208–21. Epub 2011/11/11. DOI:10.1002/cncr.26636
61. Qian Y, Wei C, Lee F Eun-Hyung, Campbell J, Halliley J, Lee JA, Cai J, Kong YM, Sadat E, Thomson E, Dunn P, Seegmiller AC, Karandikar NJ, Tipton CM, Mosmann T, Sanz I, Scheuermann RH. Elucidation of seventeen human peripheral blood B-cell subsets and quantification of the tetanus response using a density-based method for the automated identification of cell populations in multidimensional flow cytometry data. Cytometry B Clin Cytom. 2010;78 Suppl 1:S69–82. Epub 2010/09/21. DOI:10.1002/cyto.b.20554
62. Cheung RK, Utz PJ. Screening: CyTOF-the next generation of cell detection. Nat Rev Rheumatol. 2011;7:502–3. Epub 2011/07/27. DOI: 10.1038/nrrheum. 2011.110
63. Yao Y, Liu R, Shin MS, Trentalange M, Allore H, Nassar A, Kang I, Pober JS, Montgomery RR. CyTOF supports efficient detection of immune cell subsets from small samples. J Immunol Methods. 2014;415:1–5. Epub 2014/12/03. DOI:10.1016/j.jim.2014.10.010
64. Roselli M, Cereda V, di Bari MG, Formica V, Spila A, Jochems C, Farsaci B, Donahue R, Gulley JL, Schlom J, Guadagni F. Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology. 2013;2:e27025. DOI:10.4161/onci.27025
65. Santegoets SJ, Stam AG, Lougheed SM, Gall H, Jooss K, Sacks N, Hege K, Lowy I, Scheper RJ, Gerritsen WR, van den Eertwegh AJ, de Gruijl TD. Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. J Immunother Cancer. 2014;2:31. DOI:10.1186/s40425-014-0031-3